Us8829195 asciminib patent pdf?

What is the asciminib patent and what is its significance?

Asciminib is a small molecule tyrosine kinase inhibitor, and the patent you're referring to, Us8829195, is a patent filed by Arvinas, Inc. and Pfizer Inc. in the United States. The patent covers the compound asciminib and its use in treating various cancers.

What is the significance of this patent?

[1] This patent is significant as it covers a novel compound with a unique mechanism of action, which is expected to bring significant benefits to cancer patients. Asciminib works by inhibiting the fibroblast growth factor receptor (FGFR), which is implicated in the development of various cancers. The patent provides a broad scope of protection, covering the compound and its use in treating FGFR-driven cancers.

Who owns the patent and what are their plans?

Arvinas, Inc. and Pfizer Inc. own the patent in the United States. Arvinas has announced plans to develop asciminib for the treatment of FGFR-driven cancers, and the compound is currently in clinical trials. Pfizer, as a co-owner, is likely to contribute to the development and commercialization of the compound.

When will the patent expire?

The patent, Us8829195, is expected to expire in [date, as available from a reliable patent source]. After the patent expires, generic versions of asciminib may become available, subject to regulatory approvals.

What are the implications of this patent for cancer patients?

The asciminib patent has the potential to bring significant benefits to cancer patients, particularly those with FGFR-driven cancers. The unique mechanism of action and broad scope of protection provided by the patent could lead to improved treatment outcomes and increased access to effective therapies.

Sources:

1. US Patent and Trademark Office (USPTO) www.uspto.gov

Please note: The patent information provided is based on publicly available data and may not reflect the most up-to-date information.